MYD88 and primary central nervous system lymphoma: A pilot study provided evidence that the MYD88 mutation can be reliably detected by a combination of Sanger sequencing and ddPCR in the cell-free DNA (cfDNA) taken from 1 mL of CSF in patients with CNS lymphomas [72].